AstraZeneca opens $1B Kendall Square R&D hub amid China dealmaking spree

AstraZeneca inaugurated a new R&D facility in Kendall Square, Boston, backed by a $1 billion investment, signaling continued commitment to U.S. biotech innovation. The move comes amid a series of Chinese partnerships, highlighting a dual-track strategy of domestic expansion and international collaboration. The opening underscores the resilience of the Boston biotech cluster despite broader industry volatility.